TY - JOUR
T1 - Impaired angiopoietin/Tie2 signaling compromises Schlemm's canal integrity and induces glaucoma
AU - Kim, Jaeryung
AU - Park, Dae Young
AU - Bae, Hosung
AU - Park, Do Young
AU - Kim, Dongkyu
AU - Lee, Choong Kun
AU - Song, Sukhyun
AU - Chung, Tae Young
AU - Lim, Dong Hui
AU - Kubota, Yoshiaki
AU - Hong, Young Kwon
AU - He, Yulong
AU - Augustin, Hellmut G.
AU - Oliver, Guillermo
AU - Koh, Gou Young
N1 - Funding Information:
We thank Intae Park for proofreading of the manuscript, Yoshikazu Nakaoka (Osaka University) for providing Angpt1fl/fl mice, Sean J. Morrison (University of Texas Southwestern) for providing Angpt1-GFP mice, Nicholas Gale (Regeneron Pharmaceuticals) for providing Angpt2-lacZ mice, and Masanori Hirashima (Kobe University) for providing Vegfr2fl/fl mice. This study was supported by the Institute of Basic Science (IBS-R025-D1-2015 to GYK) and funded by the Ministry of Science and ICT, Republic of Korea.
PY - 2017/10/2
Y1 - 2017/10/2
N2 - Primary open-angle glaucoma (POAG) is often caused by elevated intraocular pressure (IOP), which arises due to increased resistance to aqueous humor outflow (AHO). Aqueous humor flows through Schlemm's canal (SC), a lymphatic-like vessel encircling the cornea, and via intercellular spaces of ciliary muscle cells. However, the mechanisms underlying increased AHO resistance are poorly understood. Here, we demonstrate that signaling between angiopoietin (Angpt) and the Angpt receptor Tie2, which is critical for SC formation, is also indispensable for maintaining SC integrity during adulthood. Deletion of Angpt1/Angpt2 or Tie2 in adult mice severely impaired SC integrity and transcytosis, leading to elevated IOP, retinal neuron damage, and impairment of retinal ganglion cell function, all hallmarks of POAG in humans. We found that SC integrity is maintained by interconnected and coordinated functions of Angpt-Tie2 signaling, AHO, and Prox1 activity. These functions diminish in the SC during aging, leading to impaired integrity and transcytosis. Intriguingly, Tie2 reactivation using a Tie2 agonistic antibody rescued the POAG phenotype in Angpt1/Angpt2-deficient mice and rejuvenated the SC in aged mice. These results indicate that the Angpt-Tie2 system is essential for SC integrity. The impairment of this system underlies POAGassociated pathogenesis, supporting the possibility that Tie2 agonists could be a therapeutic option for glaucoma.
AB - Primary open-angle glaucoma (POAG) is often caused by elevated intraocular pressure (IOP), which arises due to increased resistance to aqueous humor outflow (AHO). Aqueous humor flows through Schlemm's canal (SC), a lymphatic-like vessel encircling the cornea, and via intercellular spaces of ciliary muscle cells. However, the mechanisms underlying increased AHO resistance are poorly understood. Here, we demonstrate that signaling between angiopoietin (Angpt) and the Angpt receptor Tie2, which is critical for SC formation, is also indispensable for maintaining SC integrity during adulthood. Deletion of Angpt1/Angpt2 or Tie2 in adult mice severely impaired SC integrity and transcytosis, leading to elevated IOP, retinal neuron damage, and impairment of retinal ganglion cell function, all hallmarks of POAG in humans. We found that SC integrity is maintained by interconnected and coordinated functions of Angpt-Tie2 signaling, AHO, and Prox1 activity. These functions diminish in the SC during aging, leading to impaired integrity and transcytosis. Intriguingly, Tie2 reactivation using a Tie2 agonistic antibody rescued the POAG phenotype in Angpt1/Angpt2-deficient mice and rejuvenated the SC in aged mice. These results indicate that the Angpt-Tie2 system is essential for SC integrity. The impairment of this system underlies POAGassociated pathogenesis, supporting the possibility that Tie2 agonists could be a therapeutic option for glaucoma.
UR - http://www.scopus.com/inward/record.url?scp=85030556726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030556726&partnerID=8YFLogxK
U2 - 10.1172/JCI94668
DO - 10.1172/JCI94668
M3 - Article
C2 - 28920924
AN - SCOPUS:85030556726
SN - 0021-9738
VL - 127
SP - 3877
EP - 3896
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 10
ER -